pharmacological part -grant 0122РКИ0052; synthetic (chemical) part - grants AP09057956, AP09057500
Piperidine derivatives are of interest to researchers considering piperidines as an effective scaffold for the synthesis of new compounds. The aim of this research was to investigate the acute toxicity and local anesthetic activity of new synthesized 4-(Naphthalen-1-yloxy)but-2-yn-1-yl)-containing piperidine derivatives. Acute toxicity tests were performed on outbred laboratory mice by subcutaneous injection of increasing concentrations of the test solutions. An initial investigation of local anesthetic activity during infiltration anesthesia was performed on guinea pigs using the Bulbring & Wajda animal model. An in-depth study of the efficacy of the most active compound was performed on a model of infiltration anesthesia of the rabbit’s abdominal wall by determining the threshold of nociception during electrical stimulation. Studied new piperidine derivatives are low-toxic substances, which are confirmed by the results of an acute toxicity study. At the stage of the primary study of local anesthetic activity during infiltration anesthesia on the experimental Bulbring and Wajda model, the LAS-251 compound showed the greatest activity, surpassing the reference drugs in terms of anesthesia index, duration of full anesthesia and total duration of action. At the stage of in-depth study, despite a longer latency period, LAS-251 has a local anesthetic effect longer than procaine and is slightly inferior to lidocaine. Results of present study are promising because complex 1-(4-(naphthalen-1-yloxy)but-2-yn-1-yl)-4-phenylpiperidine (LAS-251) with cyclodextrin showed high local anesthetic activity. This new piperidine derivative is future-oriented for prospective studies of other types of anesthesia, as a potential medicinal substance for therapeutic use in the future.
The Protocol for this study has been approved and monitored by the Local Ethics Committee of Asfendiyarov Kazakh National Medical University (Protocol No.14(120), dated 10.28.2021, with the permission to extend the study - Protocol No.1(137), dated 01.31.2023).
Asfendiyarov Kazakh National Medical University (Almaty, Republic of Kazakhstan)
pharmacological part -grant 0122РКИ0052; synthetic (chemical) part - grants AP09057956, AP09057500
Primary Language | English |
---|---|
Subjects | Basic Pharmacology |
Journal Section | Research Article |
Authors | |
Project Number | pharmacological part -grant 0122РКИ0052; synthetic (chemical) part - grants AP09057956, AP09057500 |
Publication Date | October 23, 2024 |
Submission Date | January 20, 2024 |
Acceptance Date | July 29, 2024 |
Published in Issue | Year 2024 Volume: 49 Issue: 3 |